Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 4;161(7):1670–1681. doi: 10.1097/j.pain.0000000000001858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 2. — Antagonist activity of Ab181 at rat rPAC1 CHO cell (rPAC1-CHO) against PACAP38 or maxadilan. The antagonist activity of Ab181 at the rat PAC₁ receptor was performed by measuring the potency of Ab181 in inhibiting EC₈₀ of agonist PACAP38 or maxadilan-stimulated cAMP production. PACAP6-38, a PAC₁ receptor antagonist, was used as a positive control. Full antagonist activity of Ab181 against both PACAP38 (A) and maxadilan (B) induced cAMP accumulation was observed in rPAC1-CHO cells with IC₅₀ of 20 ± 3.3 nM (n = 3) and 4.5 ± 0.1 nM (n = 2) against respective agonist.